Table 1 Demographic data and treatment history
HR + /HER2-low MBC (n = 56) | HR-/HER2-low MBC (n = 28) | |
|---|---|---|
Demographic Data | ||
Median age at start of ADC1, yrs (range) | 60.4 (23.0–81.7) | 54.0 (37.5–79.1) |
Sex, n (%) | ||
Female | 55 (98.2%) | 28 (100.0%) |
Male | 1 (1.8%) | 0 (0%) |
Ethnicity, n (%) | ||
Hispanic | 8 (14.3%) | 9 (32.1%) |
Non-Hispanic | 47 (83.9%) | 19 (67.9%) |
Unknown | 1 (1.8%) | 0 (0%) |
Race, n (%) | ||
Asian | 4 (7.1%) | 3 (10.7%) |
Black | 3 (5.4%) | 5 (17.9%) |
White | 44 (78.6%) | 18 (64.3%) |
Other/unknown | 5 (8.9%) | 2 (7.1%) |
Histology, n (%) | ||
Ductal | 41 (73.2%) | 23 (82.1%) |
Lobular | 7 (12.5%) | 2 (7.1%) |
Mixed ductal/lobular | 5 (8.9%) | 1 (3.6%) |
Other/unknown | 3 (5.4%) | 2 (7.1%) |
De novo metastatic disease, n (%) | 12 (21.4%) | 7 (25.0%) |
Sites of metastatic disease prior to ADC1 | ||
Bone | 41 (73.2%) | 20 (71.4%) |
Liver | 34 (60.7%) | 11 (39.3%) |
Lung | 20 (35.7%) | 14 (50.0%) |
CNS | 8 (14.3%) | 6 (21.4%) |
Visceral disease prior to start of ADC1 | 47 (83.9%) | 18 (64.3%) |
Treatment History | ||
Median time from MBC diagnosis to start of ADC1, months (range) | 44.0 (0.7–199.3) | 10.2 (0.5–59.6) |
Median lines of therapy prior to ADC1 by type of therapy: | ||
Medan lines ET, number (range) | 2 (0–6) | 0 (0–1) |
Median lines chemotherapy, number (range) | 2 (0–7) | 1 (0–4) |
Median total lines of therapy, number (range) | 4 (0–10) | 2 (0–5) |
Prior CDK 4/6 inhibitor use, n (%) | 45 (80.4%) | n/a |
Median time on ET for MBC, months (range) | 30.6 (0–145.0) | n/a |
Prior immunotherapy, n (%) | 13 (23.2%) | 18 (64.3%) |
